Objective To develop a disease activity index for patients with primary Sjögren's syndrome (SS):
the European League Against Rheumatism (EULAR) Sjögren's syndrome disease …

The principle of treating-to-target has been successfully applied to many diseases outside
rheumatology and more recently to rheumatoid arthritis. Identifying appropriate therapeutic …

Objective. To study the efficacy and safety of B cell depletion with rituximab, a chimeric
murine/human anti-CD20 monoclonal antibody, in patients with primary Sjögren’s syndrome (SS) …

Sjögren syndrome (SjS) is a systemic autoimmune disease that primarily affects the exocrine
glands (mainly the salivary and lacrimal glands) and results in the severe dryness of …

Objectives To develop a score for assessment of patients' symptoms in primary Sjögren's
syndrome (SS): the EULAR SS Patient Reported Index (ESSPRI). Methods Dryness, pain, …

The therapeutic management of Sjögren syndrome (SjS) has not changed substantially in
recent decades: treatment decisions remain challenging in clinical practice, without a specific …

Objectives Treat-to-target recommendations have identified ‘remission’ as a target in systemic
lupus erythematosus (SLE), but recognise that there is no universally accepted definition …

Many relapses of systemic lupus erythematosus (SLE) are preceded by a rise in antibodies
against double-stranded DNA (anti-dsDNA). We investigated whether these relapses can be …

The EULAR Sjögren's syndrome (SS) disease activity index (ESSDAI) is a systemic disease
activity index that was designed to measure disease activity in patients with primary SS. With …

Objectives To define disease activity levels, minimal clinically important improvement (MCII)
and patient-acceptable symptom state (PASS) with the primary Sjögren's syndrome (SS) …